Literature DB >> 26391946

Chronic Neuromotor Disability After Complex Cardiac Surgery in Early Life.

M Florencia Ricci1, John C Andersen2, Ari R Joffe3, Man-Joe Watt2, Elham Khodayari Moez4, Irina A Dinu4, Gonzalo Garcia Guerra3, David B Ross5, Ivan M Rebeyka5, Charlene M T Robertson6.   

Abstract

BACKGROUND AND OBJECTIVES: Little is known about chronic neuromotor disability (CND) including cerebral palsy and motor impairments after acquired brain injury in children surviving early complex cardiac surgery (CCS). We sought to determine the frequency and presentation of CND in this population while exploring potentially modifiable acute care predictors.
METHODS: This prospective follow-up study included 549 children after CCS requiring cardiopulmonary bypass at ≤6 weeks of age. Groups included those with only 1 CCS, mostly biventricular CHD, and those with >1 CCS, predominantly single ventricle defects. At 4.5 years of age, 420 (94.6%) children received multidisciplinary assessment. Frequency of CND is given as percentage of assessed survivors. Predictors of CND were analyzed using multiple logistic regression analysis.
RESULTS: CND occurred in 6% (95% confidence interval [CI] 3.7%-8.2%) of 4.5-year survivors; for 1 CCS, 4.2% (CI 2.3%-6.1%) and >1, 9.8% (CI 7%-12.6%). CND presentation showed: hemiparesis, 72%; spasticity, 80%; ambulation, 72%; intellectual disability, 44%; autism, 16%; epilepsy, 12%; permanent vision and hearing impairment, 12% and 8%, respectively. Overall, 32% of presumed causative events happened before first CCS. Independent odds ratio for CND are age (days) at first CCS, 1.08 (CI 1.04-1.12; P < .001); highest plasma lactate before first CCS (mmol/L), 1.13 (CI 1.03-1.23; P = 0.008); and >1 CCS, 3.57 (CI 1.48-8.9; P = .005).
CONCLUSIONS: CND is not uncommon among CCS survivors. The frequency of associated disabilities characterized in this study informs pediatricians caring for this vulnerable population. Shortening the waiting period and reducing preoperative plasma lactate levels at first CCS may assist in reducing the frequency of CND.
Copyright © 2015 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2015        PMID: 26391946     DOI: 10.1542/peds.2015-1879

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

1.  Neurodevelopmental outcomes at 2 and 4 years in children with congenital heart disease.

Authors:  Cheryl L Brosig; Laurel Bear; Sydney Allen; Pippa Simpson; Liyun Zhang; Michele Frommelt; Kathleen A Mussatto
Journal:  Congenit Heart Dis       Date:  2018-09-06       Impact factor: 2.007

Review 2.  Children's complex care needs: a systematic concept analysis of multidisciplinary language.

Authors:  Maria Brenner; Claire Kidston; Carol Hilliard; Imelda Coyne; Jessica Eustace-Cook; Carmel Doyle; Thelma Begley; Michael J Barrett
Journal:  Eur J Pediatr       Date:  2018-08-08       Impact factor: 3.183

3.  A clinical perspective on a pain neuroscience education approach to manual therapy.

Authors:  Adriaan Louw; Jo Nijs; Emilio J Puentedura
Journal:  J Man Manip Ther       Date:  2017-05-22

4.  Individualized Family-Centered Developmental Care: An Essential Model to Address the Unique Needs of Infants With Congenital Heart Disease.

Authors:  Amy Jo Lisanti; Dorothy Vittner; Barbara Medoff-Cooper; Jennifer Fogel; Gil Wernovsky; Samantha Butler
Journal:  J Cardiovasc Nurs       Date:  2019 Jan/Feb       Impact factor: 2.083

5.  Outcomes of Preterm Infants With Congenital Heart Defects After Early Surgery: Defining Risk Factors at Different Time Points During Hospitalization.

Authors:  Po-Yin Cheung; Morteza Hajihosseini; Irina A Dinu; Heather Switzer; Ari R Joffe; Gwen Y Bond; Charlene M T Robertson
Journal:  Front Pediatr       Date:  2021-01-28       Impact factor: 3.418

Review 6.  Developmental outcomes after early surgery for complex congenital heart disease: a systematic review and meta-analysis.

Authors:  Darlene Huisenga; Sacha La Bastide-Van Gemert; Andrew Van Bergen; Jane Sweeney; Mijna Hadders-Algra
Journal:  Dev Med Child Neurol       Date:  2020-03-09       Impact factor: 5.449

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.